| Literature DB >> 23702487 |
Wei-Hsin Chen1, Sheau-Ling Hsieh, Kai-Ping Hsu, Han-Ping Chen, Xing-Yu Su, Yi-Ju Tseng, Yin-Hsiu Chien, Wuh-Liang Hwu, Feipei Lai.
Abstract
BACKGROUND: A hospital information system (HIS) that integrates screening data and interpretation of the data is routinely requested by hospitals and parents. However, the accuracy of disease classification may be low because of the disease characteristics and the analytes used for classification.Entities:
Keywords: Web-based services; inborn errors; information systems; metabolism; neonatal screening; tandem mass spectrometry
Mesh:
Year: 2013 PMID: 23702487 PMCID: PMC3668606 DOI: 10.2196/jmir.2495
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1The system architecture of the Web-based newborn screening system.
Summary of the disease data collected from neonates between 2006 and 2011 (N=347,312).
| Disease | Screen markers | Suspected cases | Positive cases | Screening cutoff | Diagnostic cutoff |
| PKU | Phe | 203 | 38 | > 85.02 μM | > 220 μM |
| Hypermethioninemia | Met | 261 | 40 | > 54.12 μM | > 110 μM |
| 3-MCC deficiency | C5OH | 1093 | 142 | > 0.56 μM | > 2.2 μM |
Figure 2The concept of support vector machine (SVM) methodology is transferring the vectors (ie, cases) to a higher dimension. The optimal linear hyperplane could be obtained from the largest distances between the 2 categories.
Figure 3Training and prediction strategies.
Figure 4Boxplot of phenylalanine (Phe) showing the difference (D) between positive and suspected cases of the training data.
Figure 5Primary weight formula.
Figure 6Feature selection strategies by relevant features.
Selected markers of the three diseases.
| Diseases | Selected markersa |
| PKU | Ala; Met; Phe; C4; C16:1; Leu×Tyr |
| Hypermethioninemia | Arg; Met; Phe; Val; C4; C8; C10; C10:1; C14; C14:1 |
| 3-MCC deficiency | C3; C5OH; C6; C8; C10:1; C14; C14:1; C16×C4; C4×C16:1; Orn/C16 |
aAla: alanine; Met: methionine; Phe: phenylalanine; Leu: leucine; Tyr: tyrosine; Val: valine; Orn: ornithine; Arg: Arginine;C3: propionylcarnitine; C4: isobutyrylcarnitine; C5OH: 3-hydroxyisovalerylcarnitine; C6: hexanoylcarnitine; C8: octanoylcarnitine; C10: decanoylcarnitine; C10:1: decenoylcarnitine; C14: tetradecanoylcarnitine; C14:1: tetradecenoylcarnitine; C16: palmitoylcarnitine; C16:1: palmitoleylcarnitine.
Comparison of the current versus the proposed method. The sensitivity, specificity and accuracy are calculated from predicting the neonatal samples of 2011.
| Diseases | Methods | Sensitivity (%) | Specificity (%) | Accuracy (%) |
| PKU | Current | — | 99.971 | 99.971 |
|
| Proposed | 100 | 99.997 | 99.997 |
| Hypermethionemia | Current | — | 99.958 | 99.958 |
|
| Proposed | 100 | 99.986 | 99.986 |
| 3-MCC deficiency | Current | — | 99.711 | 99.711 |
|
| Proposed | 100 | 99.936 | 99.936 |
Comparison of the current method versus the proposed method. The numbers are obtained from predicting the neonatal samples.
| Diseases | Methods | True positives (n) | True negatives (n) | False positives (n) | False negatives (n) |
| PKU | Current | 3 | — | 21 | — |
|
| Proposed | 3 | 72,111 | 2 | 0 |
| Hypermethionemia | Current | 3 | — | 30 | — |
|
| Proposed | 3 | 72,112 | 10 | 0 |
| 3-MCC deficiency | Current | 6 | — | 209 | — |
|
| Proposed | 6 | 72,255 | 46 | 0 |